QSIQuantum-Si Incorporated Class A Common Stock

Proteus launch delayed to Q2 2027 as company cuts costs and eyes $4B market opportunity.

Moby summary of Quantum-Si incorporated's Q2 2026 earnings call

Quantum-Si Inc (QSI) delays Proteus launch to Q2 2027, cuts workforce by 20%, and targets a $4 billion non-human proteomics market opportunity.

Quantum-Si (NASDAQ:QSI) said it has moved the planned launch of its Proteus protein sequencing platform to the second quarter of 2027 from the end of 2026, citing the need for an additional integrated instrument design cycle before production. The company also announced a targeted workforce reductio

QuantumSi Incorporated (QSI) delivered earnings and revenue surprises of +15.39% and +4.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Quantum-Si (NASDAQ:QSI) reported first-quarter 2026 revenue of $258,000 and reiterated that the year will be a transition period focused on development and market preparation for its next-generation Proteus protein sequencing platform. President and Chief Executive Officer Jeff Hawkins said the com

Moby summary of Quantum-Si incorporated's Q1 2026 earnings call

QuantumSi Incorporated (QSI) delivered earnings and revenue surprises of +16.67% and -35.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Joining me today are Jeffrey Alan Hawkins, our President and Chief Executive Officer, as well as Jeffry R. Keyes, our Chief Financial Officer. The results of this progress were highlighted in our recent announcement regarding the successful completion of sequencing on fully integrated Proteus instruments.